FDA panel backs speedy approval of Intercept's liver drug 07.04.2016 23:23 Reuters (Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously backed the accelerated approval of Intercept Pharmaceuticals Inc's drug to treat a rare liver condition.
